TRIM33 and cancer: Antibodies targeting the nuclear matrix protein (NXP-2) and transcription intermediary factor 1γ (TIF-1γ) are highly specific to DM and one study has suggested a possible association between anti-NXP-2 and anti-TIF-1γ autoantibodies and cancer, neither of which was statistically significant [25].